MASTERING THE ARTOF BACTERIAL SKIN INFECTION TREATMENT

With

THE DERMATOLOGIST’S

№1 CHOICE FOR BACTERIAL

SKIN INFECTIONS1

NO.1 CHOICE PRESCRIBED BY DERMATOLOGISTS1

*Methicillin-resistant S. aureus; **MSSA: Methicillin-susceptible S. aureus.

#Beta-lactams (oral), macrolides such as erythromycin, aminoglycosides such as neomycin and gentamycin, tetracyclines, mupirocin

Fusidic acid (FUCIDIN®), an ideal agent to control S. aureus in skin infections3

STEROID-LIKE HIGH PENETRATION reaching the epidermis as early as 30 minutes2,3,4

BETTER SKIN PENETRATION for both intact and damaged skin vs. other antibiotic classes3#

ACHIEVES HIGHER LOCAL CONCENTRATION at site of infection vs. systemic administration2

HIGH ACTIVITY AGAINST S. aureus including MRSA* and MSSA** isolates2,3

LOW RESISTANCE PATTERNS with no cross-resistance observed with other antibiotics2,3,5

LOW INCIDENCE OF ADVERSE EVENTS and allergic reactions compared to other antibiotics2,3

A CHOICE OF CREAM OR OINTMENT6,7

30

POWER TO PENETRATENO.1 CHOICE

NO.1 CHOICE PRESCRIBED BY DERMATOLOGISTS1

FUCIDIN®- THE POWER TO PENETRATEWORKS EVEN IN THE DEEPER SKIN LAYERS2

FUCIDIN® IS FOR BOTH SUPERFICIAL AND DEEP-SEATED INFECTIONS.2,3

Fucidin® 2 % achieves > 50 % better skin penetration vs. Mupirocin in 24 hours.8,9

Adapted from Stüttgen G, et al. 1998.4Diagram of tissue concentrations of fusidic acid5 and bactericidal activity against S. aureus.10 *Skin samples excised from cadavers not later than 36 hrs post mortem, from which the horny layer of the epidermis was removed by adhesive tape stripping, to simulate diseased skin.4 **Average MIC for S. aureus. taken as 0.25 μg/ml.10 #Both fusidic acid and sodium fusidate are absorbed through intact skin and the absorption per 24 hr at 100 % Relative Humidity and 37 oC is approximately 2 % of the applied dose when the material is applied as an alcoholic solution.8 MIC (Minimum Inhibitory Concentration)

Amount of sodium fusidate penetrated from the 2 % ointment into different depths of the skin

Tissue concentrationof Fucidin® (μg/ml)4

Impetigo, folliculitis, erythrasma

Impetigo, folliculitis, furuncle, erythrasma

Paronychia

Epidermis and upper Corium

Lower Corium

Subcutaneous fatty tissue

2953 x MIC**738,2

141,0

20,8

4,4

83 x MIC

18 x MIC

MUPIROCINA mean of 0,24 %absorbed after 24 hr8

0,24 %

Bactericidalactivity against

S. aureus10

564 x MIC

~ 2

% O

F A

PPLI

ED D

OSE

ABSO

RB

ED P

ER 2

4 H

OU

RS#

#9

POWER TO PENETRATE

FUCIDIN® - PENETRATES INTACT AND DAMAGED SKIN AT APPROXIMATELY THE SAME RATE AS TOPICAL STEROIDS.3

NO.1 CHOICE

Adapted from Schöfer H, et al, 2010 2

*Clinical success measured as treatment response ("cured" or "improved") in superficial skin infections; #Mean healing time

FUCIDIN® (SODIUM FUSIDATE) OINTMENT

FUCIDIN® (FUSIDIC ACID)CREAM

CLINICAL RESPONSE RATE (%)

CO

ND

ITIO

N

0 % 100 %20 % 40 % 60 % 80 %

over 7 days 100 %n=52

(abscesses, boils, paronychia, infected wounds) n=49

over 7.1 days# 100 %

n=50

over 7.9 days#

(abscesses, boils, paronychia, infected wounds)

98 %

n=93

over 7 days 97 %

(impetigo, folliculitis, infected trauma, infected dermatosis) n=104

over 7 days 95 %

IMPETIGO

SOFT TISSUE INFECTIONS

SKIN SEPSIS

FACIAL IMPETIGO

ACUTE SKIN SEPSIS

SKIN INFECTIONS

n=19(unspecified)

over 14 days 95 %

BACTERIAL INFECTIONS (WOUNDS)

ABSCESS

IMPETIGO

FOLLICULLITIS

BOIL

FUCIDIN® - FIRST CHOICE - FIRST LINETREATMENT FOR IMPETIGO AND/OR STAPHYLOCOCCAL PRIMARY SKIN INFECTIONS1,2

CLINICAL RESPONSE RATES* IN SKIN AND SOFT TISSUE INFECTIONS2

Data on file Leo pharmaceuticals

Data on file Leo pharmaceuticals (ICD-10 card)

Image Sourced from Shutterstock

Image Sourced from Shutterstock

Image Sourced from Adobe Stock

FIRST CHOICE - FIRST LINE

Mupirocin use has been associated with

the development of bacterial resistance12

Mupirocin resistance has been reported for both methicillin-

sensitive and methicillin-resistant strains of S. aureus, and may be

associated with previous use of mupirocin in patients treated for

long periods of time.5,12

100 % ISOLATES WERE RESISTANT TO ≥ 3 ANTIBIOTIC

CLASSES11

79 % WERE RESISTANT TO 4 ANTIBIOTIC

CLASSES11

85 % OF NASAL SWABS INDICATED MRSA11

89 % OF ISOLATES

WERE SUSCEPTIBLE

TO FUSIDIC ACID (FUCIDIN®)11

0 % MRSA RESISTANCE

TO FUCIDIN® REPORTED11

74 % WERE RESISTANT TO 5 ANTIBIOTIC

CLASSES11

MRSA RESISTANCE REPORTED IN NASAL SWABS AMONG TB PATIENTS IN KZN PROVINCE, SOUTH AFRICA11

LOW RESISTANCEFIRST CHOICE - FIRST LINE

For HCP use only

References: 1. Impact Rx Data (D6A) July 2019. 2. Schofer H, Simonsen L. Fusidic acid in dermatology: an updated review. Eur J Dermatol 2010;20(1):6-15. 3. Rigopoulos D, Larios G. Fusidic acid: a valuable agent for controlling Staphylococcus aureus skin infections. Acta Derm Venereol 2008; Suppl 216: 7–13. 4. Stuttgen G, Bauer E. Penetration and Permeation into Human Skin of Fusidic Acid in Different Galenical Formulation. Drug Res 1988;38(5):730-735. 5. Shittu AO, Lin J. Antimicrobial susceptibility patterns and characterization of clinical isolates of Staphylococcus aureus in Kwazulu-Natal province, South Africa. BMC Infect Dis 2006;6:125. [Online] 2006 Jul 28 [Cited] 2017 May 15. Available from URL: http://www.biomedcentral.com/1471-2334/6/125. 6. Fucidin® Ointment approved package insert, July 1984. 7. Fucidin® Cream approved package insert, September 1986. 8. Winkelman W, Gratton D. Topical Antibacterials. Clin Dermatol 1989;7(3):156-162. 9. Knight AG, Vickers CFH, Percival A. The percutaneous absorption of antibacterial substances. Br J Derm 1969; 81(4): 88. 10. Bogdanovich T, Ednie LM, Shapiro S, et al. Antistaphylococcal Activity of Ceftobiprole, a New Broad-Spectrum Cephalosporin. Antimicrob Agents Chemother 2005;49(10):4210-4219. 11. Heysell SK, Shenoli SV, Catterick K, et al. Prevalence of methicillin-resistant Staphylococcus aureus nasal carriage among hospitalised patients with tuberculosis in rural KwaZulu-Natal. S Afr Med J 2011;101:332-334. 12. Leyden JJ. The Role of Topical Antibiotics in Dermatologic Practice [online] 25 June 2003 [cited 28 February 2019]; Available from URL: https://www.medscape.org/viewarticle/457542_6.

FUCIDIN® CREAM. Each gram contains 20 mg (2 % m/m) fusidic acid. Reg. No. Q/20.1.6/128. FUCIDIN® OINTMENT. A 20.1.6. Each gram contains 20 mg sodium fusidate. Ref. No. G2410 (Act 101/1965). Under license from LEO Pharmaceutical Products, Ballerup, Denmark. For full prescribing information refer to the package insert approved by the medicines regulatory authority. 2019102910170445

Adcock Ingram Limited. Reg. No. 1949/034385/06 Private Bag X69, Bryanston, 2021, South AfricaTelephone + 27 11 635 0000

www.adcock.com

LEPE

TTA

083

415

643

1 12

104T

VALUABLE DERMATOLOGICAL TREATMENTS

S. aureus primary cutaneous infections on apparently normal skin:3

• Impetigo• Folliculitis• Abscesses

• Furuncles• Carbuncles• Acute paronychia

FOR PRIMARY BACTERIAL SKIN INFECTIONS*2

FUCIDIN®

*Impetigo and/or staphylococcal primary skin infections

FUSIDIC ACID IS A VALUABLE TREATMENT FOR PRIMARY AND SECONDARY SKIN INFECTIONS CAUSED BY S. AUREUS,2,6,7AND ITS USEFULNESS IS FURTHER INCREASED BY COMBINATION WITH STEROIDS2

Eradicate Bacterial Skin Infections with the Global First Choice*2

VALUABLE TREATMENT